结直肠癌的靶向治疗药物研究进展

王政, 邹建军, 李哲, 沈素, 余俊先

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (24) : 2077-2081.

PDF(849 KB)
中国药学杂志
PDF(849 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (24) : 2077-2081. DOI: 10.11669/cpj.2016.24.001
消化道肿瘤药物的研发与临床应用专栏

结直肠癌的靶向治疗药物研究进展

  • 王政1, 邹建军2, 李哲1, 沈素1, 余俊先1*
作者信息 +

Targeted Drugs in Colorectal Cancer

  • WANG Zheng1, ZOU Jian-jun2, LI Zhe1, SHEN Su1, YU Jun-xian1*
Author information +
文章历史 +

摘要

结直肠癌是常见的消化道肿瘤,多数患者在确诊时已属于中晚期,化疗+靶向药物治疗能有效提高患者的中位生存期。已上市的靶向药物分为两类,单克隆抗体和小分子激酶抑制剂,前者有贝伐珠单抗、西妥昔单抗、帕尼单抗、雷莫芦单抗,后者包括瑞戈非尼、阿柏西普。根据药物的机制分类,贝伐珠单抗和帕尼单抗作用于肿瘤细胞表皮生长因子受体(EGFR),其余4个作用于肿瘤新生血管内皮生长因子(VEGF)及其受体(VEGFR)。目前,我国药企自主研发的阿帕替尼、法米替尼用于结直肠癌的Ⅲ期临床试验也在紧密进行中。然而结直肠癌靶向治疗所面临的耐药性和毒性反应亦不容忽视。未来的努力方向是研究发现新靶点、新药物,例如PD-1抑制剂可能为结直肠癌患者带来新的生机。

Abstract

Colorectal cancer is a common gastrointestinal cancer which always diagnosed too late. However, nowadays the median survival of patients has been effectively improved by chemotherapy plus targeted therapy. Targeted drugs on the market can be divided into two categories, monoclonal antibodies and small molecule kinase inhibitors(TKI). Bevacizumab, cetuximab, panitumumab, ramucirumab are monoclonal antibody. TKIs are as followed:regorafenib, ziv-aflibercept.According to the drug mechanism, bevacizumab and panitumumab target at epidermal growth factor receptor(EGFR)on tumor cells. While the remaining four drugs target at vascular endothelial growth factor(VEGF) and its receptor(VEGFR). Clinical trials of Chinese domestic drugs apatinib and famitinib are undergoing. Currently, the main issue of colorectal cancer targeted therapy is how to overcome drug resistance and reducetoxicity. The direction of future work is finding new targets, new drugs in colorectal cancer, such as PD-1 inhibitors which may bring new vitality to worldwide patients.

关键词

结直肠癌 / 靶向药物 / 表皮生长因子受体 / 血管内皮生长因子 / 血管内皮生长因子受体

Key words

colorectal cancer / targeted drug / epidermal growth factor receptor / vascular endothelial growth factor / vascular endothelial growth factor receptor

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
王政, 邹建军, 李哲, 沈素, 余俊先. 结直肠癌的靶向治疗药物研究进展[J]. 中国药学杂志, 2016, 51(24): 2077-2081 https://doi.org/10.11669/cpj.2016.24.001
WANG Zheng, ZOU Jian-jun, LI Zhe, SHEN Su, YU Jun-xian. Targeted Drugs in Colorectal Cancer[J]. Chinese Pharmaceutical Journal, 2016, 51(24): 2077-2081 https://doi.org/10.11669/cpj.2016.24.001
中图分类号： R965   

参考文献

[1] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2] SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[3] CHEN W Q,ZHENG R S,ZHANG S W, et al. Report of cancer incidence and mortality in China, 2012 [J]. Chin Cancer(中国肿瘤), 2016,25(1):1-8.
[4] SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2012 [J].CA Cancer J Clin, 2012, 62(1):10-29.
[5] ZHOU A P, WANG J W. Hot spots about target therapy of metastasis colorectal cancer on the 2013 ASCO conference[J]. Chin J New Drugs(中国新药杂志),2013, 22(17): 2033-2037.
[6] ARNOLD D,RE T,BENNOUNA J, et al.Bevacizumab(BEV) plus chemotherapy(CT) continued beyond first progression in patients with metastatic colorectal cancer(mCRC) previously treated with BEV plus CT:results of a randomized phase III intergroup study(TML study) [J]. J Clin Oncol,2012,30(suppl):abstr CRA3503.
[7] LEMMON M A,SCHLESSINGER J. Cell signaling by receptor tyrosine kinases [J]. Cell,2010,141(7): 1117-1134.
[8] BROGNARD J,HUNTER T. Protein kinase signaling networks in cancer[J].Curr Opin Genet Dev, 2011, 21(1): 4-11.
[9] ZAMECNIKOVA A. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer [J]. Expert Opin Drug Discov,2014, 9(1): 77-92.
[10] LEVITZKI A. Tyrosine kinase inhibitors: views of selectivity, sensitivity,and clinical performance [J]. Annu Rev Pharmacol Toxicol, 2013, 53: 161-185.
[11] SAWYER T K, WU J C, SAWYER J R, et al. Protein kinase inhibitors: breakthrough medicines and the next generation[J]. M Expert Opin Invest Drugs, 2013, 22(6): 675-678.
[12] HANG L, WANG J. The investigation of TKIs [J]. Chem Reagents(化学试剂), 2014, 36(10): 901-906.
[13] FOLKMAN J. Tumor angiogenesis: therapeutic implication [J]. N Engl J Med, 1971, 285(21): 1182-1186.
[14] FRANCAVILLA C, MADDALUNO L, CAVALLARO U. The functional role of cell adhesion molecules in tumor angiogenesis [J]. Seminars Cancer Biol, 2009, 19(5): 298-309.
[15] KISS I, BORTLICEK Z, MELICHAR B, et al. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma [J]. Anticancer Res, 2014, 34(2):949-954.
[16] AN X Y. The new strategies of targeted drugs[J]. Acta Biophys Sin(生物物理学报), 2010, 26(3):180-193.
[17] NAGY J A, DVORAK A M, DVORAK H F. VEGF-A and the induction of pathological angiogenesis [J]. Annu Rev Pathol Mech Dis, 2007, 2: 251-275.
[18] JIN C H, WANG A H, CHEN J M, et al. Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer[J]. J Int Med Res, 2011, 39(6):2129-2140.
[19] HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004, 350(23): 2335-2342.
[20] EI B X, ZHANG Z Y, XU Y P. Clinical research of bevacizumab plus different kinds of chemotherapieutics for metastatic colorectalcancer[J]. Chin Pharm J(中国药学杂志), 2014,49(22):2039-2042.
[21] IAN W L, HAN W,TANG S Z. Progress in research of multi-target drugs and their development strategy [J]. Guangdong Chem Ind(广东化工), 2014,8(41):69-72.
[22] SARTORE A, ZEEPELLINI A, AMATU A, et al. Regorafenib in metastatic colorectal cancer [J]. Expert Rev Anticancer Ther, 2014, 14(3): 255-265.
[23] QI Y. The approval of ziv-aflibercept by FDA [J]. J Int Pharm Res(国际药学研究杂志), 2012, 39(5): 390.
[24] SONG M. Progression of ziv-aflibercept on metastatic colorectal cancer [J]. Chin J New Drugs Clin Rem(中国新药与临床杂志), 2015,9(34):692-696.
[25] LI J, QIN S, XU J, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. Clin Oncol,2016, 34(13):1448-1454.
[26] LANKHORST S,KAPPERS M H, VAN ESCH J H,et al. Hypertension during vascular endothelial growth factor inhibition: focus on nitricoxide,endothelin-1,and oxidative stress[J]. Antioxid Redox Signal,2014,20(1): 135-145.
[27] ZHOU A, ZHANG W, CHANG C, et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib[J].Cancer Chemother Pharmacol, 2013, 72(5):1043-1053.
[28] LI H M, YU Y H. Key molecules in targeted therapies for metastatic colorectal cancer [J]. World Chin J Digestol(世界华人消化杂志), 2014, 22(3): 350-358.
[29] SHEEMA S, ROBERTO B, PAOLO M, et al. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer[J]. J Theor Biol,2016,389:263-273.
[30] HU J X, FAN X M. Research progress of targeted therapy in colorectal cancer [J]. World Clin Drugs(世界临床药物), 2015, 36(6):366-369.
[31] MCLELLAN B, CIARDIELLO F, LACOUTURE E, et al.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management [J]. Annals Oncol, 2015,10(26): 2017-2026.
[32] LU Y Y, GUO X L. Advance development of immunotherapy on malignant melanoma with targeting inhibition of PD-L1/PD-1[J]. Chin Pharm J(中国药学杂志),2015, 50(22):1931-1935.
[33] ZHANG X W, REN X B. The clinical research of PD-1inhibitors [J]. Med Philosophy(医学与哲学),2015,36(2):22-28.

基金

国家重大新药创制专项(2010ZX09401-301)
PDF(849 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉